87
Participants
Start Date
June 4, 2018
Primary Completion Date
January 1, 2026
Study Completion Date
June 1, 2026
Prazosin
This is an antagonist of the alpha1 receptor for noradrenaline. It is FDA approved for the treatment of hypertension, and has also been used for benign prostatic hypertrophy (BPH). Most recently, it has been found to be helpful for symptoms of PTSD in some but not all participants.
Placebo
This is a capsule containing an inert substance, in order to provide blinding to participants and study staff of when participants are on active medication and when they are not during the later portions of the trial.
VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
VA Office of Research and Development
FED